This review article from Future Oncology summarizes the efficacy of the latest therapeutic agents available for the treatment of patients with relapsed multiple myeloma.
Browsing: Disease Area > Rare tumors
This case report details a rare example of a woman with metastatic and rapidly progressive secretory paraganglioma who responded rapidly and durably to lenvatinib.
Researchers have identified a novel potential therapeutic target for an aggressive form of pediatric glioma.
To mark Rare Disease Day, Oncology Central brings you an exclusive opinion piece written by two of the principal investigators of a pivotal immunotherapy clinical trial designed specifically for rare cancer patients.
Researchers have demonstrated that IL-6 controls resistance to radiation in oral squamous cell carcinoma.
Researchers discover that inhibiting EZH2 leads to the reduced expression of specific oncogenes involved in the development of multiple myeloma
Low-dose brachytherapy studies have demonstratedequivalent local and distant tumor control with reduced radiation complications – read more in this perspective article.
Randomized trials often require involvement of hundreds of patients to identify clinically meaningful differences – in terms or rare cancer, read as Ian Olver debates whether clinical trials should be approached differently in this opinion piece from Future Oncology.